Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Hims & Hers, a health and wellness platform, is set to introduce at-home lab testing capabilities through the acquisition of ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report)’s share price hit a new 52-week high during trading on Wednesday after Bank of America raised their price target on the stock from $18.00 to $21.

BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

This is the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.

There are wonders of the visual world—this week, dive into the hidden beauty of the plants that keep us alive, the less ...

There are wonders of the visual world—this week, dive into the hidden beauty of the plants that keep us alive, the less ...